Alan A. Musso - 31 Oct 2023 Form 3 Insider Report for AILERON THERAPEUTICS INC (RNTX)

Role: Director
Signature: /s/ Manuel C. Alves-Aivado, M.D., Ph.D., as attorney-in-fact for Alan Musso
Issuer symbol: RNTX
Transactions as of: 31 Oct 2023
Net transactions value: $0
Form type: 3
Filing time: 02 Nov 2023, 20:51:59 UTC
Previous filing: 09 Aug 2023
Next filing: 19 Jan 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ALRN	Stock Option (right to buy)							31 Oct 2023	Common Stock	17,064	$4.63	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On October 31, 2023, the Issuer completed its merger with Lung Therapeutics, Inc. (the "Merger") in accordance with the terms of the Agreement and Plan of Merger, dated October 31, 2023. In connection with the Merger, the Issuer assumed the Reporting Person's option to purchase 100,000 shares of Lung Therapeutics, Inc. common stock originally granted on May 9, 2022, which option was converted into an option to purchase 17,064 shares of Issuer common stock. The shares underlying the option vest annually on each anniversary of the grant date until the third anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer on each applicable vesting date.

Content

On October 31, 2023, the Issuer completed its merger with Lung Therapeutics, Inc. (the "Merger") in accordance with the terms of the Agreement and Plan of Merger, dated October 31, 2023. In connection with the Merger, the Issuer assumed the Reporting Person's option to purchase 100,000 shares of Lung Therapeutics, Inc. common stock originally granted on May 9, 2022, which option was converted into an option to purchase 17,064 shares of Issuer common stock. The shares underlying the option vest annually on each anniversary of the grant date until the third anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer on each applicable vesting date.

Remarks:

Exhibit 24.1 Power of Attorney